中金发表报告指，三生制药(01530.HK) 去年收入91.08亿元人民币(下同)，按年升16.5%；净利润20.9亿元，按年升34.9%，经调整经营性净利润23.19亿元，按年升18.8%，业绩好于该行预期，主要因核心品种稳健增长及联营公司收益增长。
中金基本维持三生制药2025年经调整净利润预测为24.07亿元，引入2026年经调整净利润预测26.02亿元。维持“跑赢行业”评级，由于近期港股流动性回暖和板块估值中枢上升，上调目标价68.8%至
13.5港元，另认为公司管线布局丰富，创新产品进入收获期。(ha/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.